BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in upcoming healthcare conferences. The company will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:50 a.m. ET and at the Barclays Global Healthcare Conference in Miami Beach, Florida, on March 16, 2022, at 2:35 p.m. ET. Both presentations will be available via live audio webcast on BioCryst's website. The company focuses on developing innovative treatments for rare diseases, including ORLADEYO (berotralstat) and RAPIVAB (peramivir).

RESEARCH TRIANGLE PARK, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 9:50 a.m. ET. The event will be held virtually.

The company also will present at the Barclays Global Healthcare Conference in Miami Beach, Florida on Wednesday, March 16, 2022, at 2:35 p.m. ET.

Links to a live audio webcast and replay of these presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

 

FAQ

When will BioCryst Pharmaceuticals present at the Cowen 42nd Annual Health Care Conference?

BioCryst Pharmaceuticals will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:50 a.m. ET.

What date will BioCryst Pharmaceuticals present at the Barclays Global Healthcare Conference?

BioCryst Pharmaceuticals will present at the Barclays Global Healthcare Conference on March 16, 2022, at 2:35 p.m. ET.

How can I listen to BioCryst's presentations at the healthcare conferences?

You can access live audio webcasts of BioCryst's presentations on their website in the Investors & Media section.

What is the focus of BioCryst Pharmaceuticals in drug development?

BioCryst Pharmaceuticals focuses on discovering novel medicines for rare diseases where significant unmet medical needs exist.

What are some of the approved products from BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has approved products including ORLADEYO (berotralstat) and RAPIVAB (peramivir injection).